
Breast cancer [17]


Developing novel models of disease and vaccination in Ab- and FcR-humanized mice
Pierre Bruhns

Antibody-based anti-tumor immunotherapy
Pierre Bruhns

A synthetic glycopeptide for anti-tumor immunotherapy: from design to first use in human
Sylvie Bay

Clinical development of cancer vaccines
Claude Leclerc

iSPLICE: Regulation of alternative splicing by RNAi and non-coding RNAs
Christian Muchardt

Cécile Peltekian
Institut Carnot Pasteur MS

Cassandre Von Platen
Clinical Core
Clinical Project Manager Experienced in study management and coordination of cross-functionnal project teams according to the quality standards and defined timelines and budget. With a demonstrated history of working in clinical operation management for […]

Molecular Retrovirology
Simon Wain-Hobson

Lucie Peduto
Stroma, Inflammation and Tissue Repair
Lucie Peduto obtained her PhD in Tumor Biology at the University of Lausanne/CHUV (Switzerland) and Ecole Pratique des Hautes Etudes in Paris. She joined the lab of Carl Blobel at Sloan-Kettering Institute (New York) […]

Claude Leclerc
Major Federating Program Vaccinology

Laurence Mulard
Organic Chemistry

Eric Batsché
Our research focuses on mechanisms underlying the epigenetic regulation of alternative RNA splicing. In particular, we are interested in deciphering the cross-talks between the chromatin organization, and both transcriptional and spliceosome machineries which involve […]

Christian Muchardt
Dr. Muchardt is Director of Research, class 1, at the CNRS. His laboratory at the Institut Pasteur is studying the role of epigenetic in the onset of diseases, with a special interest for cancer […]

Simon Wain-Hobson
Molecular Retrovirology
